Natera, INC Form 4 insider transactions

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold shares to cover tax withholding obligations related to vesting RSUs.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., reports the vesting of Restricted Stock Units and subsequent sale of shares to cover tax obligations.

Jonathan Sheena, co-founder of Natera, Inc., reports transactions involving common stock and restricted stock units, including sales to cover tax obligations.

Jonathan Sheena, co-founder of Natera, Inc., sold shares of common stock on April 3rd and 4th, 2025, under pre-arranged Rule 10b5-1 trading plans.

Director Marcus Gail Boxer reports exercising stock options and selling Natera (NTRA) shares on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold a portion of his holdings in Natera common stock on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Michael Brophy, CFO of Natera, Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Natera's CEO, Steven Chapman, reports the vesting of restricted stock units and subsequent sales of common stock to cover tax obligations and under a pre-arranged trading plan.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., reports the acquisition and disposal of Natera's common stock and restricted stock units.

Director Monica Bertagnolli acquired 2,877 shares of Natera, Inc. through the issuance of Restricted Stock Units (RSUs) on March 28, 2025.

Natera CEO Steven Chapman sold 6,702 shares of common stock on March 17, 2025, to cover tax obligations related to vesting RSUs.

Natera's CFO, Michael Brophy, sold shares of common stock on March 17, 2025, to cover tax withholding obligations related to vesting RSUs.

Jonathan Sheena, co-founder of Natera, Inc., reports the sale of common stock shares in multiple transactions on March 17 and 18, 2025, according to a Form 4 filing with the SEC.

Matthew Rabinowitz, Executive Chairman of Natera, Inc., sold shares of common stock on March 17, 2025, to satisfy tax withholding obligations related to the vesting of RSUs.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., sold shares of common stock on March 17, 2025, to cover tax withholding obligations related to vesting RSUs.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold a portion of his common stock to cover tax withholding obligations related to vesting RSUs.

John Fesko, President and Chief Business Officer of Natera, Inc., sold shares of common stock on March 17, 2025, to satisfy tax withholding obligations related to the vesting of RSUs.

Michael Brophy, CFO of Natera, Inc., reports acquiring 2,032 shares of common stock through the issuance of fully-vested Restricted Stock Units (RSUs).

Jonathan Sheena, co-founder of Natera, Inc., reports acquiring 411 shares of common stock through fully-vested Restricted Stock Units (RSUs).

Matthew Rabinowitz, Executive Chairman of Natera, Inc., reported the sale of common stock in multiple transactions on March 14, 2025, following the acquisition of restricted stock units.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., reports the acquisition of 1,740 Restricted Stock Units (RSUs) fully vested at issuance.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., reported acquiring 2,040 shares of common stock through the issuance of fully-vested Restricted Stock Units (RSUs).

John Fesko, President and Chief Business Officer of Natera, Inc., reports acquiring 2,040 shares of common stock through the issuance of fully-vested Restricted Stock Units (RSUs).

Natera CEO Steven Chapman reports the acquisition of 6,702 shares of Natera, Inc. common stock through the issuance of fully-vested Restricted Stock Units (RSUs).

Director Marcus Gail Boxer reported the sale of Natera, Inc. shares on March 12, 2025, according to a Form 4 filing with the SEC.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold a portion of his holdings in common stock under a pre-arranged Rule 10b5-1 trading plan.

Natera's CEO, Steven Leonard Chapman, sold a portion of his common stock holdings on March 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Sheena, co-founder of Natera, Inc., sold shares of common stock on February 26, 2025, according to a Form 4 filing with the SEC.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., reports the acquisition of shares through RSU vesting and subsequent sale to cover tax obligations.

John Fesko, President and Chief Business Officer of Natera, Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.